HIM
ASBPW

HGC Investment Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

HGC Investment Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$5.07K – 117
2023
Q3 		$5.07K Hold
100,000
– – ﹤0.01% 99
2023
Q2 		$6K Buy
+100,000
New +$3.67K ﹤0.01% 113

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

HGC Investment Management's ASBPW Position: Q4 2023 in Review

HGC Investment Management sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2023, closing a stake of 100,000 shares — an estimated $5.07K sold.

HGC Investment Management first reported a position in ASBPW in Q2 2023 and held it in 2 quarters. The position peaked at $6K in Q2 2023. 35 funds tracked by Wall St. Rank hold ASBPW as of Q4 2023.

  • HGC Investment Management reported no remaining Aspire Biopharma Warrant position as of Q4 2023 after selling out during the quarter.
  • HGC Investment Management sold 100,000 Aspire Biopharma Warrant shares in Q4 2023, an estimated $5.07K.
  • HGC Investment Management first reported a position in Aspire Biopharma Warrant in Q2 2023 and held it in 2 quarters.
  • HGC Investment Management's Aspire Biopharma Warrant position peaked at $6K in Q2 2023.
  • 35 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2023.

Based on HGC Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.